Centella asiatica extract
Centella asiatica extract is an orally active herbal extract. Centella asiatica extract scavenges free radicals, increases stratum corneum hydration, improves epidermal barrier function, and reduces skin redness and skin pH. Centella asiatica extract inhibits pro-inflammatory cytokines, suppresses p38 MAPK phosphorylation, reduces mast cell infiltration, and decreases the expression of TNF-α, IL-4, IL-5, IL-6, IL-17, CXCL9, iNOS and COX-2. Centella asiatica extract upregulates the expression of BDNF and downregulates the expression of VGLUT1, and exhibits neuroprotective effects under hypoxic conditions. Centella asiatica extract inhibits pro-inflammatory M1 macrophage polarization and prevents adipose tissue senescence. Centella asiatica extract can be used in studies related to hypoxia-induced neurological dysfunction, atopic dermatitis, and obesity-induced insulin resistance.
For research use only. We do not sell to patients.
- CAS No.: 84696-21-9
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[3]|
TNF-α |
IL-6 |
IL-5 |
IL-17 |
In Vitro
Centella asiatica extract (100-500 µg/mL; 1 h pre-incubation; 24 h stimulation with IFN-γ/TNF-α) dose-dependently reduces the expression levels of pro-inflammatory proteins COX-2 and IL-6 in IFN-γ/TNF-α-stimulated human keratinocyte HaCaT cells[3].
Centella asiatica extract (200 μg/mL; pre-incubated for 30 min prior to 24 h LPS stimulation) alters the mRNA expression of Il10 in RAW264.7 mouse macrophages stimulated with low glucose and LPS (HY-D1056)[4].
Centella asiatica extract (200 μg/mL; 30 min pre-incubation prior to 24 h LPS stimulation) inhibits the polarization of high glucose plus LPS-stimulated RAW264.7 mouse macrophages toward pro-inflammatory M1 macrophages by reducing the mRNA expression of Ccl2, Il6, Il1b and Tnf[4].
Centella asiatica extract (CA) (10-1000 µg/mL; 24 h) shows no cytotoxicity against HaCaT human keratinocytes at concentrations up to 500 µg/mL, while cytotoxicity is observed starting from the concentration of 600 µg/mL[3].
Centella asiatica extract (100-500 µg/mL) has detectable polyphenol and flavonoid contents, and exhibits concentration-dependent ABTS and DPPH free radical scavenging activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HaCaT human keratinocytes
-
Concentration:10, 40, 70, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 µg/mL
-
Incubation Time:24 h
-
Result:Showed no cytotoxicity in HaCaT cells at concentrations ranging from 10 µg/mL to 500 µg/mL, with cell viability remaining above 100% relative to the control.
Reduced cell viability to 48.46% at 600 µg/mL CA.
-
Cell Line:IFN-γ/TNF-α-stimulated HaCaT human keratinocytes
-
Concentration:100, 300, 500 µg/mL
-
Incubation Time:1 h pre-incubation; 24 h stimulation with IFN-γ/TNF-α
-
Result:Reduced COX-2 expression to 0.9-fold, 0.6-fold, and 0.4-fold relative to the stimulated control at 100 µg/mL, 300 µg/mL, and 500 µg/mL CA, respectively.
Reduced IL-6 expression to 0.9-fold, 0.4-fold, and 0.3-fold relative to the stimulated control at 100 µg/mL, 300 µg/mL, and 500 µg/mL CA, respectively.
-
Cell Line:RAW264.7 mouse macrophage cell line (high glucose condition)
-
Concentration:200 μg/mL
-
Incubation Time:30 min pre-incubation prior to 24 h LPS stimulation
-
Result:Alleviated mRNA relative expression levels of the M1 pro-inflammatory markers Ccl2, Il6, Il1b, and Tnf.
Had no effect on Il10 and Mgl1 mRNA expression levels.
Showed inconsistent elevation of Cd206 mRNA expression under high glucose+LPS conditions.
In Vivo
Centella asiatica extract (80 µg/cm2; topical skin administration; once daily; 14 days; 200 mg/kg; oral administration; once daily; 14 days) alleviates DNCB-induced atopic dermatitis symptoms in BALB/c mice, including ear swelling, lymph node enlargement, skin hyperplasia, mast cell infiltration, and the expression of pro-inflammatory cytokines and signaling proteins[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Danio rerio (larvae, 0-2 hours post-fertilization to 9 days post-fertilization, hypoxic-ischemic injury model)[2]
-
Dosage:1.25 μg/mL; 2.5 μg/mL; 5 μg/mL
-
Administration:continuous; 6 days
-
Result:Increased average BDNF expression to 36.2 at 3 days post-fertilization and 35.92 at 9 days post-fertilization with 1.25 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Increased average BDNF expression to 34.82 at 3 days post-fertilization and 36.26 at 9 days post-fertilization with 2.5 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Increased average BDNF expression to 36.19 at 3 days post-fertilization and decreased it to 34.09 at 9 days post-fertilization with 5 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Decreased average VGLUT1 expression to 27.54 at 3 days post-fertilization and increased it to 32.95 at 9 days post-fertilization with 1.25 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
Increased average VGLUT1 expression to 32.65 at 3 days post-fertilization and decreased it to 31.19 at 9 days post-fertilization with 2.5 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
Increased average VGLUT1 expression to 33.45 at 3 days post-fertilization and decreased it to 32.08 at 9 days post-fertilization with 5 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
-
Animal Model:BALB/c (8-week-old female, DNCB-induced atopic dermatitis)[3]
-
Dosage:80 µg/cm2 (skin local); 200 mg/kg (p.o.)
-
Administration:skin local; daily; 14 days; p.o.; daily; 14 days
-
Result:Reduced ear thickness 1.3-fold (80 µg/cm2 skin local) and 1.2-fold (200 mg/kg oral) relative to untreated DNCB-induced mice.
Reduced lymph node weight 1.6-fold in both treatment groups compared to untreated DNCB-induced mice.
Reduced epidermal thickness 2.7-fold (skin local) and 1.9-fold (oral) relative to untreated DNCB-induced mice.
Reduced dermal thickness 10.1-fold (skin local) and 5.9-fold (oral) relative to untreated DNCB-induced mice.
Reduced mast cell infiltration 4.4-fold (skin local) and 3.7-fold (oral) compared to untreated DNCB-induced mice.
Reduced mRNA expression of TNF-α 5.6-fold (skin local) and 12.9-fold (oral), IL-5 5.6-fold (skin local) and 11.5-fold (oral), IL-10 3.2-fold (skin local) and 9.5-fold (oral), IL-6 12.6-fold (skin local) and 1.7-fold (oral), as well as iNOS, COX-2, and CXCL9 relative to untreated DNCB-induced mice.
Reduced protein expression of TNF-α 2.7-fold (skin local) and 1.6-fold (oral), COX-2 2.9-fold (skin local) and 1.7-fold (oral), MAC-1 1.5-fold (skin local) and 1.6-fold (oral), and IL-6 3.4-fold in both groups relative to untreated DNCB-induced mice.
Suppressed p-p38 protein expression 1.4-fold (skin local) and 1.7-fold (oral) relative to untreated DNCB-induced mice.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 84696-21-9
-
SMILES
[Centella asiatica extract]
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (Need ultrasonic)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Centella asiatica extract Related Classifications
HY-N18667 Related Classifications
Powered by Bioz